Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
vestipitant/paroxetine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| vestipitant/paroxetine | DRUG | - |
Inclusion criteria: * Primary diagnosis of Generalised Social Anxiety Disorder as defined in DSM-IV. * Capable of giving informed consent and willing to comply with the study requirements. * Women of childbearing potential must agree to one of a number of defined acceptable methods of birth control...
Vestipitant is an investigational small molecule being studied for tinnitus, social phobia, depressive disorder, and anxiety disorders. It is in Phase 2 clinical development and is not approved by the FDA. The drug is being developed by GSK plc.
Vestipitant is a small molecule being studied for tinnitus, social phobia, depressive disorder, and anxiety disorders. Its specific molecular target has not been disclosed in available clinical trial information. It is in Phase 2 development by GSK plc.
Vestipitant is being developed by GSK plc, which trades under the ticker GSK. The drug is an investigational small molecule in Phase 2 clinical trials for tinnitus, social phobia, depressive disorder, and anxiety disorders.
Vestipitant is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. GSK plc is the developer, and the drug is being studied for tinnitus, social phobia, depressive disorder, and anxiety disorders.
Vestipitant has been studied in three completed Phase 2 trials: NCT00343707 for depressive disorder and anxiety disorders, NCT00394056 for tinnitus, and NCT00403962 for social phobia. These trials were conducted in Sweden, the United Kingdom, Denmark, Germany, Norway, and South Africa.
Vestipitant has been studied in combination with paroxetine in clinical trials for tinnitus and social anxiety disorder. However, no alternative names for Vestipitant itself have been disclosed in the available trial information.